Level Four Advisory Services LLC Has $952,000 Stock Position in Enovis Co. (NYSE:ENOV)

Level Four Advisory Services LLC lessened its position in shares of Enovis Co. (NYSE:ENOV) by 40.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 21,705 shares of the company’s stock after selling 14,825 shares during the quarter. Level Four Advisory Services LLC’s holdings in Enovis were worth $952,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ENOV. Charles Schwab Investment Management Inc. boosted its stake in shares of Enovis by 14.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 600,819 shares of the company’s stock valued at $25,865,000 after purchasing an additional 73,623 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in Enovis by 3.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 66,668 shares of the company’s stock worth $2,870,000 after acquiring an additional 2,123 shares during the period. FMR LLC raised its position in shares of Enovis by 20.5% during the 3rd quarter. FMR LLC now owns 2,840 shares of the company’s stock valued at $122,000 after acquiring an additional 484 shares during the last quarter. Bridgewater Associates LP lifted its stake in shares of Enovis by 80.1% in the 3rd quarter. Bridgewater Associates LP now owns 17,588 shares of the company’s stock valued at $757,000 after purchasing an additional 7,823 shares during the period. Finally, MetLife Investment Management LLC boosted its position in shares of Enovis by 9.4% in the 3rd quarter. MetLife Investment Management LLC now owns 28,839 shares of the company’s stock worth $1,242,000 after purchasing an additional 2,476 shares during the last quarter. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Enovis Stock Down 2.9 %

Shares of NYSE:ENOV opened at $37.74 on Monday. The company has a 50 day moving average price of $42.06 and a two-hundred day moving average price of $43.35. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27. The company has a market capitalization of $2.15 billion, a PE ratio of -17.23 and a beta of 2.05. Enovis Co. has a 52 week low of $35.14 and a 52 week high of $62.79.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.92 by $0.06. The business had revenue of $560.98 million during the quarter, compared to analysts’ expectations of $555.14 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. Analysts forecast that Enovis Co. will post 2.79 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC dropped their price objective on Enovis from $65.00 to $64.00 and set a “buy” rating for the company in a report on Thursday, February 27th.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.